A Novel Organotellurium Compound (RT-01) as a New Antileishmanial Agent
- 1 January 2009
- journal article
- research article
- Published by Korean Society for Parasitology in The Korean Journal of Parasitology
- Vol. 47 (3), 213-218
- https://doi.org/10.3347/kjp.2009.47.3.213
Abstract
Leishmaniasis is a neglected disease and endemic in developing countries. A lack of adequate and definitive chemotherapeutic agents to fight against this infection has led to the investigation of numerous compounds. The aim of this study was to investigate the effect of RT-01, an organotellurane compound presenting biological activities, in 2 experimental systems against Leishmania amazonensis. The in vitro system consisted of promastigotes and amastigotes forms of the parasite, and the in vivo system consisted of L. amazonensis infected BALB/c mice, an extremely susceptible mouse strain. The compound proved to be toxic against promastigotes and amastigotes. The study also showed that treatment with RT-01 produces an effect similar to that treatment with the reference antimonial drug, Glucantime, in L. amazonensis infected mice. The best results were obtained following RT-01 intralesional administration (720 mu g/kg/day); mice showed significant delay in the development of cutaneous lesions and decreased numbers of parasites obtained from the lesions. Significant differences in tissue pathology consisted mainly of no expressive accumulation of inflammatory cells and well-preserved structures in the skin tissue of RT-01-treated mice compared with expressive infiltration of infected cells replacing the skin tissue in lesions of untreated mice. These findings highlight the fact that the apparent potency of organotellurane compounds, together with their relatively simple structure, may represent a new avenue for the development of novel drugs to combat parasitic diseases.Keywords
This publication has 33 references indexed in Scilit:
- Bcl-2 expression and apoptosis induction in human HL60 leukaemic cells treated with a novel organotellurium(IV) compound RT-04Food and Chemical Toxicology, 2008
- The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitisJournal of Dermatological Science, 2008
- Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101British Journal of Dermatology, 2008
- Novel Involvement of the Immunomodulator AS101 in IL-10 Signaling, via the Tyrosine Kinase FerAnnals of the New York Academy of Sciences, 2007
- Advances in leishmaniasisThe Lancet, 2005
- Tellurium-based cysteine protease inhibitors: evaluation of novel organotellurium(IV) compounds as inhibitors of human cathepsin BBioorganic & Medicinal Chemistry Letters, 2005
- Efficacy of trypan®: a diminazene based drug as antileishmanial agentActa Tropica, 2004
- Leishmaniasis: current situation and new perspectivesComparative Immunology, Microbiology and Infectious Diseases, 2004
- Antibabesial effect of the immunomodulator AS101 in mice: role of increased production of nitric oxideParasite Immunology, 1996
- A new immunomodulating compound (AS-101) with potential therapeutic applicationNature, 1987